5 Top-Ranked Stocks With Rising P/E That Investors Can Bet On

The screening narrowed a universe of >7,700 stocks to 66 using rising P/E and momentum criteria (EPS growth estimate >= prior year, sequential 4/12/24-week price outperformance vs S&P, 20-day volume >=50k, Zacks Rank <=2). Five highlighted Zacks Rank #2 names are H&R Block (HRB), Sportsman's Warehouse (SPWH), Sera Prognostics (SERA), Veeva Systems (VEEV) and Workhorse Group (WKHS) with average four-quarter earnings surprises of 1.57%, 38.37%, 15.54%, 7.47% and 19.89%, respectively. The piece is a constructive, strategy-focused buy signal for stocks with rising P/Es and consistent momentum, but is editorial/strategy-level and unlikely to move broader markets.

Analysis

Rising P/Es are a two-headed signal: true earnings-revision-driven expansion (sustainable over quarters) versus flow-driven multiple expansion (vulnerable to short-term reversals). Distinguish these by watching consecutive upward analyst revision days and insider/strategic buybacks (structural) versus spikes in retail volume and options open interest (transient). A regime shift in real rates or a single large negative revision can erase 20–40% of momentum-driven gains within 4–12 weeks; conversely, contract wins and durable revenue visibility can convert a momentum rally into a multi-quarter rerating.

Second-order winners differ by business model: recurring SaaS revenue with long contracts and high gross margins (durable cross-sell) will outlast retail/EV momentum names that depend on inventory cycles, unit economics and supply partnerships. For small-cap or highly speculative hardware plays, dependence on OEM contracts, battery supply and access to dealer fleets are choke points that can bottleneck revenue even as retail interest inflates multiples. Diagnostic/biotech names live and die on reimbursement and clinical-readout cadence — positive approval/reimbursement signals can trigger multi-quarter outperformance, but failures produce binary collapses.

Practical timing: treat price momentum as a near-term signal (days–weeks) and earnings/contract revision flow as the durable signal (months). Use options to monetize skew (buy protection on longs or buy cheap calls where upside is tied to binary catalysts) and size responsibly — cap single-name exposure in high-volatility cases to 0.5–3% notional. The market tends to underprice longevity of enterprise SaaS tails and overprice ephemeral retail/ev narratives; lean long the former, hedge or avoid the latter unless properly hedged.

Key Decisions for Investors

• Long VEEV (2–3% portfolio). Initiate a 12-month position: buy stock or buy 12–18 month call spread (e.g., 1x 12mo ATM call / sell 1x 12mo +25% OTM) to cap cost. Rationale: durable contract tails and cross-sell; target +25–40% in 6–12 months; stop-loss if negative revision streak >2 successive quarters or if quarterly ARR growth misses consensus by >200bps.
• Pair trade: Long HRB / Short SPWH (net 1–1 exposure, 1–2% portfolio each leg). Trade window 1–3 months into tax-seasonality and post-inventory cleanup for retail. Expect convergence of fundamentals; target relative outperformance of HRB vs SPWH of 10–15%; unwind if SPWH same-store-sales surprise positively or HRB issues guidance cut.
• Protective short on WKHS (0.5–1% portfolio). Use 3–6 month put spread to limit capital at risk (buy 1x 6mo ITM put / sell 1x 6mo deeper-OTM put). Thesis: high dilution and execution risk; target downside >30% on adverse contract or funding news; keep position size small due to gamma risk.
• Event-driven speculative long SERA (0.5–1% portfolio). Buy 9–12 month OTM calls or small equity stake sized for binary risk around clinical/reimbursement catalysts. Reward is asymmetric if milestones hit (>2x), but treat as binary: cap exposure and hedge with biotech index put if sector sells off.